Levi & Korsinsky reminds Regeneron Pharmaceuticals investors that the deadline to seek lead plaintiff appointment in a securities class action is September 14, 2026. The lawsuit, filed in the Southern District of New York, covers shareholders who purchased Regeneron securities between August 1, 2025 and May 15, 2026. The complaint alleges that Regeneron and certain senior officers made misleading statements about the Phase III Fianlimab-Libtayo study, which later failed to meet its primary progression-free survival endpoint. Regeneron shares fell from a class period high of $731.77 on April 28, 2026 to $629.68 after the May 15, 2026 announcement, a decline of $102.09 per share or approximately 13.95%. The named individual defendants include George D. Yancopoulos, Israel Lowy, and Ryan Crowe, who are alleged to have had control over the company's disclosures.
Regeneron Pharmaceuticals IncSecurities class action lawsuit alleging misleading statements about Phase III study failure.